UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045744
Receipt number R000052222
Scientific Title Study on postprandial blood glucose response test food intake in healthy subjects.
Date of disclosure of the study information 2021/10/15
Last modified on 2022/04/25 16:42:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on postprandial blood glucose response test food intake in healthy subjects.

Acronym

Study on postprandial blood glucose response test food intake in healthy subjects.

Scientific Title

Study on postprandial blood glucose response test food intake in healthy subjects.

Scientific Title:Acronym

Study on postprandial blood glucose response test food intake in healthy subjects.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of food ingredient on cognitive functions.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood glucose level

Key secondary outcomes

Blood insulin level
Blood Triglyceride level


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Placebo food (a single time intake) > 2-week washout > Test food (a single time intake)

Interventions/Control_2

Test food (a single time intake) > 2-week washout > Placebo food (a single time intake)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1. Men and women between the ages of 20 and under 75 who wish to voluntarily participate in clinical trials and obtain written consent.
2. Subjects who can maintain their daily habits during the test period.

Key exclusion criteria

1. Subjects with serious illness (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) or mental illness.
2. Subjects with a history of serious illness. (diabetes, heart disease, liver disease, kidney disease, cancer, etc.)
3. Subjects who have large changes in diet and exercise and cannot maintain their daily lifestyle.
4. Subjects with food or medicine allergies.
5. Subjects who are taking food for specified health uses or health food products.
6. Others considered as inappropriate for this study by the physician.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Yoshinori
Middle name
Last name Hamachiyo

Organization

Kewpie Corporation

Division name

Senior executive officer

Zip code

182-0002

Address

2-5-7, Sengawa-cho, Chofu-shi, Tokyo, Japan.

TEL

03-5384-7760

Email

yoshinori_hamachiyo@kewpie.co.jp


Public contact

Name of contact person

1st name Tatsuo
Middle name
Last name Uetake

Organization

CXwellness, Inc.

Division name

Representative director

Zip code

103-0023

Address

516 Nihonbashinagatani Bldg.,3-1-6,Nihonbashihoncho, Chuo-ku, Tokyo, Japan.

TEL

03-6225-5601

Homepage URL


Email

uetake@cx-wellness.com


Sponsor or person

Institute

CXwellness, Inc.

Institute

Department

Personal name



Funding Source

Organization

Kewpie Coroporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

Tel

03-6240-1162

Email

info@ueno-asagao.clinic


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 10 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

17

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 08 Month 04 Day

Date of IRB

2021 Year 08 Month 04 Day

Anticipated trial start date

2021 Year 08 Month 04 Day

Last follow-up date

2021 Year 10 Month 27 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 10 Month 13 Day

Last modified on

2022 Year 04 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052222